Strong Delivery Masks an Unresolved LFP Margin Question
Revenue and profit each grew 28% and 27% YoY, yet management held the FY28 PAT target flat—₹1,100 Cr unchanged. The earnings call reveals why: the LFP cathode margin story, the linchpin of the long-term case, remains opaque and unsubstantiated when challenged.
Himadri's Q1 FY-2027 result is a genuine beat—revenue ₹1,432 Cr and net profit ₹228 Cr each outpaced prior-year by 28% and 27%, with margins stable at 20.1% OPM and 15.3% NPM. Yet in the earnings call, management reaffirmed the FY28 PAT target of ₹1,100 Cr without upgrading it, despite this strong organic run. That decision, combined with analyst Tanvi Warekar's sharp challenge to the LFP margin math and the MD's deflection on cost structure, reveals the real story: the company's long-term case hinges on LFP profitability at China parity pricing, and that margin economics remain unproven and opaque.
Where the profit came from
Q1's PAT ₹228 Cr is organic—no one-time MTM or exceptional items distort the headline. The profit grew 27% YoY on revenue growth of 28%, reflecting stable operational leverage and a modest product-mix upgrade. Segment-by-segment: Coal Tar Derivatives and Speciality Carbon Black remain the core (high margins, stable volumes), and Birla Tyres added ₹127 Cr in Q1 sales on the path to EBITDA breakeven in FY27. The headwind: mining operations halted awaiting environmental licensing, eliminating a prior ₹25 Cr quarterly EBIT contribution—material for Q1, but offset by Birla ramp and immaterial to the full-year PAT target (<2% of ₹1,100 Cr guidance).
₹1,432 Cr
no adjustment needed
22%
stable, ₹313 Cr absolute
₹25 Cr
licensing pause; non-structural
Management's claims vs. what holds up
Strong profitability growth via product mix shift → PAT ₹228 Cr (+27% YoY) on revenue ₹1,432 Cr (+28% YoY); margins stable at 20.1% OPM, 15.3% NPM
LFP will be priced competitive vs China at profitable margins → Analyst Tanvi Warekar showed input cost + China parity pricing yield negative gross spread; MD deflected without cost substantiation
Anode pilot plant shows customer traction, approval path on track → Supplied Stage B samples globally; 1.5–2 year approval timeline advancing; approvals expected by plant commissioning
₹1,100 Cr PAT by FY28 target unchanged after Q1 → MD Anurag: 'Definitely' reaffirmed, 'no negative' assumptions changed, 'things positive only'
The third and fourth claims are well-supported. The anode 200 MTPA facility came live in April and is actively supplying Stage B samples globally—a tangible de-risking vs. prior pilot-only status. The FY28 PAT target reaffirmation is unhedged: management said 'definitely' unchanged. But the second claim—LFP profitability at China parity—is where credibility broke. When Tanvi Warekar showed that lithium carbonate input costs plus China's current ₹[price] per tonne pricing yield a negative gross spread, the MD responded not with cost substantiation but with 'Excel sheet won't work' and 'that's confidential.' That evasion is the quarter's turning point: the bull case for ₹3,000 Cr LFP revenue by FY28 is entirely contingent on LFP margins, and the margin claim is now credibility-scarred.
What changed on this call
LFP roadmap de-risked
upgradePhase 1 split to 2K MT (Q3 FY27) + 40K MT (FY28) vs. original 40K MT monolith; customer trials (IBC partnership) validating demand; allows pivot if economics deteriorate
New capex program announced
newCNT (₹70 Cr), SSCB (₹170 Cr), total ₹2B over FY27–28; fully self-funded, no incremental debt; diversifies revenue upside beyond LFP
Birla Tyres ramp confirmed
neutral₹127 Cr Q1 sales, targeting EBITDA breakeven FY27; 4–5 year path to ₹3,000 Cr; validates turnaround execution
Mining licensing delayed
downsideOperations paused Q1, ₹25 Cr EBIT lost; 3–6 month visibility gap; immaterial to PAT target but reduces near-term upside optionality
Bull case vs. bear case
The honest read: This is a Hold. Himadri is a high-quality execution machine—Q1 beat confirms that—but the bull case is a call option on two unproven claims: (1) LFP is profitable at China parity pricing, and (2) new products (CNT, SSCB, anode) scale to the forecasted revenue. On claim 1, the MD has already forfeited credibility by deflecting rather than substantiating. On claim 2, the company is guarded and vague. The capex cycle is real; if returns disappoint, FCF tightens and the ₹1,100 Cr FY28 PAT target becomes a ceiling, not a stepping stone. The market's +12% pop by day 5, now fading to ₹750.65 (8% below all-time high), reflects this: believers exist, but skeptics rightfully hold back enthusiasm until LFP margin is proven.
How the street is positioned
Price action: The result announcement (Wed Jul 15, ₹681.55 close) triggered a day-1 pop of +5.99%, which expanded to +12.96% by day 3 and held near +12.72% by day 5. The stock now trades at ₹750.65 (as of Jul 31), sitting 8.37% below its all-time high of ₹819.25. It is above its 20-day (₹724.32), 50-day (₹680.34), and 200-day (₹531.25) simple moving averages—a bullish posture. But the 8% drawdown from ATH and RSI of 66 (neutral, not overbought) suggest the market is cautiously optimistic rather than euphoric about the long-term story.
Institutional positioning: FII ownership ticked up to 5.98% (from 5.75% prior quarter, +23 bps), and DII to 3.21% (from 3.10%, +11 bps). Promoter holding remains stable at 52.50%. Both FII and DII accumulation, albeit modest, signals institutional faith in the growth roadmap. Bulk-block activity in the past 6 months shows no promoter or insider-linked selling near the highs—a green flag. The accumulation is measured, not aggressive, consistent with a story that requires proof (LFP margin validation) before conviction deepens.
Valuation context: The stock has rebounded 79.37% from its 52-week low of ₹418.50, and is 8% off ATH. In a 52-week range of ₹418.5–₹819.25, the current ₹750.65 is in the upper quartile, suggesting the market has priced in a reasonable portion of the growth upside. The pop-and-fade pattern (day-1 +6%, day 5 +13%, now -8% from peak) is textbook for a 'beat on numbers, but macro story unclear' narrative—institutions are buying the execution track record, not yet the LFP thesis.
Risks, ranked by how much they should concern a holder
LFP margin viability unproven at China parity pricing; cost structure opaque
HighLFP is 35% of the ₹3,000 Cr revenue guidance and a prime driver of the ₹1,100 Cr FY28 PAT target. If margin is negative or razor-thin (as analyst's cost analysis suggests), ₹3,000 Cr LFP revenue becomes immaterial to bottom-line profit, and the entire FY28 target is at risk. MD's evasion on cost disclosure and refusal to substantiate viability is a major credibility gap.
Capex cycle headwind and execution risk; ₹2B committed over FY27–28
MediumLarge capex relative to FCF (₹900 Cr annual run-rate) absorbs cash and delays FCF growth. If any of the five new products (LFP, anode, CNT, SSCB, anthraquinone) slip in commissioning or ramp-up, or if returns are lower than assumed, balance sheet tightens and debt could rise. No debt path revealed despite ₹2B commitment and self-funding claim.
Customer concentration in battery materials (LFP, anode); only IBC publicly named; others in trial phase
MediumLFP demand hinges on IBC's 7 GW India facility (commissioning Q4 FY27) and unspecified China/global OEM trials. If IBC's facility delays or anode approval is slower than the 1.5–2 year timeline (MD says 'advanced' but no specific gate date), demand visibility evaporates and capex becomes stranded.
Mining licensing delays; ₹25 Cr EBIT lost Q1, 3–6 month visibility gap
LowImmaterial to overall ₹1,100 Cr FY28 PAT guidance (<2% of target), but reduces near-term optionality and quarterly beat potential. Regulatory process outside management's control.
Forex volatility persists; MD's 'last quarter' claim unsubstantiated by hedging policy disclosure
LowFX loss booked Q1 (amount unspecified). Export revenue (global specialty carbon black, anode precursor pitch) provides some natural hedge, but if rupee weakens further, losses can reoccur. MD gave no revised hedging ratios or forward cover plan.
What to watch next
1 · LFP Phase 1 (2,000 MTPA) commissioning in Q3 FY27 (Oct–Dec 2026)
Sample C trials with IBC must begin on schedule. This is the inflection point: if trials progress and customer approval timelines narrow, the LFP margin opacity becomes a rearview concern. If trials slip or customer hesitation emerges, the ₹3,000 Cr revenue guidance is at risk. Watch for quarterly commentary in Q3 FY27 earnings on sample progression and customer feedback.
2 · FY28 capex execution and new-product ramp visibility (FY28 H1, Apr–Sep 2027)
Management must disclose (a) LFP Phase 1 full 40K MT on-time delivery, (b) CNT facility commissioning, (c) initial revenue/margin data from anode (already ramping), and (d) revised guidance on SSCB and anthraquinone start dates. The ₹1,100 Cr PAT target is a test of execution discipline; if any capex slips, re-rating downward is justified.
3 · Mining licensing completion (H1 FY28, visibility 3–6 months per MD)
Minor but not zero: ₹25 Cr EBIT reinstatement would incrementally validate execution and slightly raise FY28 PAT toward upper end of range. Delay beyond mid-FY28 signals regulatory friction and reduces quarter-by-quarter beat potential.
The honest read
Himadri delivered a solid Q1—no ambiguity on the 28% revenue and 27% PAT growth. The Mahistikry anode facility is live and sampling, Birla Tyres is ramping, and the capex roadmap is concrete. But this quarter is not a step-change; it's steady execution of a strategy whose profitability remains unproven. The market's +12% pop and subsequent fade to ₹750.65 (8% off ATH) is the correct reading: buy the execution track record, but wait for LFP margin proof before committing conviction. The number to track from here is not the topline—it's the FY28 PAT delivery of ₹1,100 Cr and the LFP gross margin disclosed in that result. If management delivers both, the stock reprices upward. If LFP margins disappoint (or remain opaque), the stock treads water or re-rates lower. Until that test, Hold.
Rating: Hold. Confidence: 7/10.
The Q1 beat is real and operational excellence is proven. But the bull case is a call option on LFP profitability, and the margin has lost credibility this call. Wait for Q3 FY27 trial updates and FY28 capex/margin disclosure before upgrading.
Informational and educational content only. Not investment advice.